Eutropics Pharmaceuticals will present data from two recent clinical investigations at the 55th Annual American Society for Hematology Meeting to be held in New Orleans, LA December 7-11, 2013. These studies demonstrate the medical utility of Eutropics’ proprietary biomarker platform, PraediCare-Dx (aka BH3 profiling), in predicting patient response to cancer treatment.
Help employers find you! Check out all the jobs and post your resume.
